GET DAILY SIGNALSChiron Real Estate (XRN) Q3 2026 Earnings: Revenue Up 8.3% During Portfolio Transition
Key Takeaways
- Chiron Real Estate reported third quarter 2026 total revenue of $40.34 million, up 8.3% year over year.
- Net loss attributable to common stockholders widened to $8.86 million, or -$0.67 per share, versus -$0.45 per share a year earlier.
- Funds From Operations (FFO), a key profitability measure for real estate companies, fell to $0.50 per share from $1.00, while Core FFO declined 33% to $0.75 per share.
- Rental revenue dropped 9.5% as the company continued selling its outpatient medical portfolio, partially offset by new revenue from its seniors housing operating segment.
- The company completed its $173.2 million acquisition of The Pinnacle, reinforcing its strategic pivot toward seniors housing.
- You can find more details about Chiron Real Estate's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Explore Trending AI Robots to see AI-driven trading strategies currently gaining traction in the market.
Why This Report Matters for Investors
XRN is a healthcare REIT that has been moving away from a traditional landlord model toward a more active approach focused on seniors housing. The latest quarter offers an early look at how that shift is unfolding. Rental income is falling as outpatient medical assets are sold off, while revenue from the new seniors housing operations is starting to appear. I am watching closely to see whether the revenue growth and execution on the strategy can eventually support stronger per-share results, or if the wider loss points to a tougher transition ahead.
The Quarter in Detail
For the three months ended September 30, 2026, total revenue reached $40.34 million, an 8.3% rise from $37.25 million in the same period last year. That top-line improvement did not carry through to earnings. The net loss attributable to common stockholders expanded to $8.86 million, or -$0.67 per share, from a loss of $6.0 million, or -$0.45 per share, a year earlier.
FFO per share, the standard REIT metric that adds back depreciation, dropped to $0.50 from $1.00. Core FFO, which excludes certain one-time items, fell 33% to $0.75 per share from $1.12. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Lower rental revenue and higher expenses drove the declines.
Rental revenue declined 9.5% to $33.5 million because of the ongoing sales of the outpatient medical portfolio and the changing asset mix. This was partly offset by $6.24 million in resident fees and services revenue from the new Seniors Housing Operating Portfolio. General and administrative expenses rose to $7.7 million from $4.86 million, with about $2 million of that tied to retirement and transition costs for the Chief Investment Officer.
Market Reaction and Strategy Update
Sentiment around XRN has centered more on the long-term repositioning than on any single quarterly figure. The company had already withdrawn its 2026 guidance and reduced the monthly dividend by roughly 36%, showing a focus on retaining capital for the transformation. The latest results fit that pattern: revenue grew and the seniors housing segment contributed for the first time, yet the wider loss, lower FFO, and transition costs highlight the near-term costs of the pivot. Investors seem to be balancing the potential of the seniors housing strategy against current earnings pressure and higher leverage.
What to Watch Next
The pace of the portfolio shift remains the key item to follow. The company has now closed on the $173.2 million acquisition of The Pinnacle, expanding its seniors housing presence, while it continues to market the outpatient medical assets for sale. The speed and pricing of those sales will affect leverage, liquidity, and future earnings.
Cost control will also matter. The third quarter included one-time expenses around the CIO change, so investors will look for G&A to stabilize. At the same time, growth in the SHOP segment’s resident fees and services revenue needs to help offset the drop in rental income. Operating metrics such as occupancy, FFO per share, Core FFO, and interest expense will show whether the larger seniors housing platform can support improved per-share results and renewed confidence in the revised strategy.
How Tickeron Tools Fit Into My Research
I often turn to Tickeron’s AI Screener when comparing healthcare REITs like this one. It lets me quickly filter for similar names, technical patterns, and AI-driven signals across the sector so I can put the quarterly numbers in better context without spending hours on manual screens. The tool has become a regular part of how I evaluate both individual stocks and broader industry trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XRN sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for XRN moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Aroon Indicator for XRN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XRN's RSI Indicator exited the oversold zone, 24 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on XRN as a result. In 50 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for XRN just turned positive on October 30, 2026. Looking at past instances where XRN's MACD turned positive, the stock continued to rise in 20 of 39 cases over the following month. The odds of a continued upward trend are 51%.
XRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.921) is normal, around the industry mean (3.130). P/E Ratio (8.167) is within average values for comparable stocks, (29.108). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (1.649). Dividend Yield (0.021) settles around the average of (0.049) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (6.013).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. XRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock slightly worse than average.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the acquisition of purpose-built healthcare facilities and leasing of those properties to strong healthcare systems and physician groups
Industry PublishingBooksMagazines
Advertisement